Partner Content Partner Content 6 Ways To Finally Drug RAS Oncogenes Are You Developing Effective Anti-RAS Therapeutics?
Partner Content Partner Content Boehringer Ingelheim to present data at RAS Summit Europe RAS- Targeted Drug Discovery Europe Conference
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
